Biocon Ltd is a pharmaceutical company based in India that specializes in developing biotechnology therapies for various diseases. With a risk rating score of 22.0, the company is considered to be of medium risk. Biocon focuses on the development, manufacturing, and supply of novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. The company operates in four segments: Generics, Biosimilars, Novel Biologics (Novels), and Research services, providing integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene.